

ICER Lowballs Critical Alzheimer's Medications

ICER's cost-effectiveness analysis doesn't wholly depict the value of new Alzheimer's medications.

⊖ Limits patient and advocate perspectives

ICER has changed the scope of this assessment, as well as the review timeline, multiple times. This has made it difficult for patients and advocates to meaningfully engage and relay critical insights.



⊖ Undervalues disease-therapy benefits

ICER's analysis diminishes the potential benefits of the medication. The analysis says that the medication's efficacy could range from small to substantial, an ambiguous range, even though clinical trial data shows a statistically significant slowing of cognitive decline.

⊖ Diminishes the needs of communities of color

Black and Hispanic Americans are disproportionately affected by Alzheimer's. Disparities in access to health care oftentimes mean that, for these groups, the burdens of the disease are heavier. Expanding treatment options and access would be particularly valuable for communities of color.

⊖ Discounts important cost considerations

The indirect costs of Alzheimer's – including social costs, unpaid caregiving and emotional burdens – are enormous. Yet ICER underestimates them by more than \$100 billion. Not incorporating these costs undervalues the benefits provided by Alzheimer's medications.

Expanding treatment access could change lives, but ICER's limited assessment stands in the way.



Institute for
Patient Access